Journal of Shanghai Jiao Tong University (Medical Science) >

2024 , Vol. 44 >Issue 7: 822 - 829

DOI: https://doi.org/10.3969/j.issn.1674-8115.2024.07.003

Topics on advances in translational medicine frontiers

Advances in drug therapy of diabetic retinopathy

  • Minghao CHEN ,
  • Peiyu LIU ,
  • Xuan WANG ,
  • Yixiang WU ,
  • Yujin JIANG ,
  • Chaoyang ZHANG ,
  • Jingfa ZHANG
Expand
  • 1.Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
    2.Department of Ophthalmology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
    3.The International Eye Research Institute of The Chinese University of Hong Kong (Shenzhen), Shenzhen 518000, China
ZHANG Chaoyang, E-mail: chaoyang.zhang@shgh.cn.
ZHANG Jingfa, E-mail: 13917311571@139.com

Received date: 2024-02-11

  Accepted date: 2024-05-22

  Online published: 2024-07-28

Supported by

National Natural Science Foundation of China(82171062)

Fold

Abstract

Diabetic retinopathy (DR) is one of the most common microvascular complications of diabetes and has become one of the leading causes of blindness and visual impairment in diabetes patients. The pathogenesis of DR is multifaceted, involving inflammation, oxidative stress, neurovascular abnormalities, and other factors that present potential targets for disease management interventions. Currently, anti-vascular endothelial growth factor (VEGF) drugs serve as the primary treatment for advanced stages of DR when irreversible neurovascular damage and visual impairment have occurred. Additionally, some patients show poor or no response to anti-VEGF treatment. There is a lack of early intervention options for the initial phases of the disease. Therefore, there is an urgent need to develop novel local or systemic therapies based on the underlying mechanisms of DR to enable early prevention and treatment with the aim of preserving patients′ vision. Medications targeting various pathways including anti-inflammatory agents (corticosteroids and nonsteroidal anti-inflammatory drugs), neurotrophic and neuroprotective drugs, drugs modulating biochemical pathways, antioxidant phytochemicals, and gene therapy can complement each other in terms of therapeutic effects to benefit a larger number of individuals affected by DR. This article reviews previous research reports on the pathogenesis, drug treatment methods, and potential therapeutic targets associated with DR in order to provide guidance for clinical practice.

Key words： diabetic retinopathy (DR); inflammation; oxidative stress; vascular endothelial growth factor (VEGF); drug therapy

Cite this article

Minghao CHEN , Peiyu LIU , Xuan WANG , Yixiang WU , Yujin JIANG , Chaoyang ZHANG , Jingfa ZHANG . Advances in drug therapy of diabetic retinopathy[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024 , 44(7) : 822 -829 . DOI: 10.3969/j.issn.1674-8115.2024.07.003

References

1 KANG Q Z, YANG C X. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications[J]. Redox Biol, 2020, 37: 101799.
2 KOLEVA-GEORGIEVA D N, SIVKOVA N P, TERZIEVA D. Serum inflammatory cytokines IL-1β, IL-6, TNF-α and VEGF have influence on the development of diabetic retinopathy[J]. Folia Med, 2011, 53(2): 44-50.
3 SADIKAN M Z, NASIR N A A, AGARWAL R, et al. Protective effect of palm oil-derived tocotrienol-rich fraction against retinal neurodegenerative changes in rats with streptozotocin-induced diabetic retinopathy[J]. Biomolecules, 2020, 10(4): 556.
4 SADIKAN M Z, ABDUL NASIR N A, BAKAR N S, et al. Tocotrienol-rich fraction reduces retinal inflammation and angiogenesis in rats with streptozotocin-induced diabetes[J]. BMC Complement Med Ther, 2023, 23(1): 179.
5 BARBER A J, GARDNER T W, ABCOUWER S F. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy[J]. Invest Ophthalmol Vis Sci, 2011, 52(2): 1156-1163.
6 METTU P S, ALLINGHAM M J, COUSINS S W. Incomplete response to anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities[J]. Prog Retin Eye Res, 2021, 82: 100906.
7 EICHENBAUM D A, AHMED A, HIYA F. Ranibizumab port delivery system: a clinical perspective[J]. BMJ Open Ophthalmol, 2022, 7(1): e001104.
8 REGILLO C, BERGER B, BROOKS L, et al. Archway phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration 2-year results[J]. Ophthalmology, 2023, 130(7): 735-747.
9 SHUGHOURY A, BHATWADEKAR A, JUSUFBEGOVIC D, et al. The evolving therapeutic landscape of diabetic retinopathy[J]. Expert Opin Biol Ther, 2023, 23(10): 969-985.
10 BROWN D M, EMANUELLI A, BANDELLO F, et al. KESTREL and KITE: 52-week results from two phase Ⅲ pivotal trials of brolucizumab for diabetic macular edema[J]. Am J Ophthalmol, 2022, 238: 157-172.
11 ABU SERHAN H, TAHA M J J, ABUAWWAD M T, et al. Safety and efficacy of brolucizumab in the treatment of diabetic macular edema and diabetic retinopathy: a systematic review and meta-analysis[J]. Semin Ophthalmol, 2024, 39(4): 251-260.
12 JOUSSEN A M, RICCI F, PARIS L P, et al. Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data[J]. Eye, 2021, 35(5): 1305-1316.
13 SAHNI J, PATEL S S, DUGEL P U, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial[J]. Ophthalmology, 2019, 126(8): 1155-1170.
14 WYKOFF C C, ABREU F, ADAMIS A P, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials[J]. Lancet, 2022, 399(10326): 741-755.
15 DUGEL P U, BOYER D S, ANTOSZYK A N, et al. Phase 1 study of OPT-302 inhibition of vascular endothelial growth factors C and D for neovascular age-related macular degeneration[J]. Ophthalmol Retina, 2020, 4(3): 250-263.
16 GONZALEZ-CORTES J H, MARTINEZ-PACHECO V A, GONZALEZ-CANTU J E, et al. Current treatments and innovations in diabetic retinopathy and diabetic macular edema[J]. Pharmaceutics, 2022, 15(1): 122.
17 HUSSAIN R M, SHAUKAT B A, CIULLA L M, et al. Vascular endothelial growth factor antagonists: promising players in the treatment of neovascular age-related macular degeneration[J]. Drug Des Devel Ther, 2021, 15: 2653-2665.
18 CHANDRASEKARAN P R, MADANAGOPALAN V G. KSI-301: antibody biopolymer conjugate in retinal disorders[J]. Ther Adv Ophthalmol, 2021, 13: 25158414211027708.
19 BOYER D S, YOON Y H, BELFORT R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema[J]. Ophthalmology, 2014, 121(10): 1904-1914.
20 WEI W B, CHEN Y X, HU B J, et al. Multicenter, prospective, randomized study of dexamethasone intravitreal implant in patients with center-involved diabetic macular edema in the Asia-Pacific region[J]. Clin Ophthalmol, 2021, 15: 4097-4108.
21 MUSHTAQ Y, MUSHTAQ M M, GATZIOUFAS Z, et al. Intravitreal fluocinolone acetonide implant (ILUVIEN?) for the treatment of retinal conditions. A review of clinical studies[J]. Drug Des Devel Ther, 2023, 17: 961-975.
22 SINGER M A, SHETH V, MANSOUR S E, et al. Three-year safety and efficacy of the 0.19-mg fluocinolone acetonide intravitreal implant for diabetic macular edema: the PALADIN study[J]. Ophthalmology, 2022, 129(6): 605-613.
23 GABR A F, KAMEL M F, ELBARAWY A A. Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema[J]. Int Ophthalmol, 2023, 43(9): 3219-3226.
24 ELBENDARY A, ELKANNISHY A H. Intravitreal diclofenac versus intravitreal bevacizumab in persistent diabetic macular edema: anatomical and functional outcome[J]. Saudi J Ophthalmol, 2018, 32(4): 303-309.
25 FEIZI S, ALEMZADEH-ANSARI M, KARIMIAN F, et al. Use of erythropoietin in ophthalmology: a review[J]. Surv Ophthalmol, 2022, 67(2): 427-439.
26 SAMSON F P, HE W L, SRIPATHI S R, et al. Dual switch mechanism of erythropoietin as an antiapoptotic and pro-angiogenic determinant in the retina[J]. ACS Omega, 2020, 5(33): 21113-21126.
27 QI Y X, SU X J, WEI L L, et al. Erythropoietin inhibits apoptosis of retinal ganglion cells induced by high glucose through JNK signaling pathway[J]. J Biol Regul Homeost Agents, 2021, 35(2): 547-557.
28 ENTEZARI M, FLAVARJANI Z K, RAMEZANI A, et al. Combination of intravitreal bevacizumab and erythropoietin versus intravitreal bevacizumab alone for refractory diabetic macular edema: a randomized double-blind clinical trial[J]. Graefes Arch Clin Exp Ophthalmol, 2019, 257(11): 2375-2380.
29 REID G, LOIS N. Erythropoietin in diabetic retinopathy[J]. Vision Res, 2017, 139: 237-242.
30 CANNING P, O′LEARY O, ALLEN L D, et al. ARA290 (cibinetide) treatment confers neuroprotective effects in diabetic retinopathy, through modulation of inflammatory mediators[J]. Invest Ophthalmol Vis Sci, 2019, 60(9): 2720.
31 LOIS N, GARDNER E, MCFARLAND M, et al. A phase 2 clinical trial on the use of cibinetide for the treatment of diabetic macular edema[J]. J Clin Med, 2020, 9(7): 2225.
32 AMATO R, DAL MONTE M, CERVIA D, et al. Neural degeneration mechanisms in diabetic retinopathy: the role of apoptosis and autophagy[J]. Acta Ophthalmol, 2017, 95(S259). DOI: 10.1111/j.1755-3768.2017.0F064.
33 VILLARROEL M, CIUDIN A, HERNáNDEZ C, et al. Neurodegeneration: an early event of diabetic retinopathy[J]. World J Diabetes, 2010, 1(2): 57-64.
34 HERNáNDEZ C, SIMó R. Somatostatin replacement: a new strategy for treating diabetic retinopathy[J]. Curr Med Chem, 2013, 20(26): 3251-3257.
35 MAZZEO A, ARROBA A I, BELTRAMO E, et al. Somatostatin protects human retinal pericytes from inflammation mediated by microglia[J]. Exp Eye Res, 2017, 164: 46-54.
36 SIMó R, HERNáNDEZ C, PORTA M, et al. Effects of topically administered neuroprotective drugs in early stages of diabetic retinopathy: results of the EUROCONDOR clinical trial[J]. Diabetes, 2019, 68(2): 457-463.
37 JULIUS A, HOPPER W. A non-invasive, multi-target approach to treat diabetic retinopathy[J]. Biomed Pharmacother, 2019, 109: 708-715.
38 SENTHILKUMARI S, SHARMILA R, CHIDAMBARANATHAN G, et al. Epalrestat, an aldose reductase inhibitor prevents glucose-induced toxicity in human retinal pigment epithelial cells in vitro[J]. J Ocul Pharmacol Ther, 2017, 33(1): 34-41.
39 TOYODA F, TANAKA Y, OTA A, et al. Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats[J]. J Diabetes Res, 2014, 2014: 672590.
40 LU Z W, FAN B, LI Y Z, et al. RAGE plays key role in diabetic retinopathy: a review[J]. Biomed Eng Online, 2023, 22(1): 128.
41 RAMIS R, ORTEGA-CASTRO J, CABALLERO C, et al. How does pyridoxamine inhibit the formation of advanced glycation end products? The role of its primary antioxidant activity[J]. Antioxidants, 2019, 8(9): 344.
42 XU J, CHEN L J, YU J, et al. Involvement of advanced glycation end products in the pathogenesis of diabetic retinopathy[J]. Cell Physiol Biochem, 2018, 48(2): 705-717.
43 VAN DEN EYNDE M D G, HOUBEN A J H M, SCHEIJEN J L J M, et al. Pyridoxamine reduces methylglyoxal and markers of glycation and endothelial dysfunction, but does not improve insulin sensitivity or vascular function in abdominally obese individuals: a randomized double-blind placebo-controlled trial[J]. Diabetes Obes Metab, 2023, 25(5): 1280-1291.
44 BAGGE S L, FOTHERINGHAM A K, LEUNG S S, et al. Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetes[J]. Med Res Rev, 2020, 40(4): 1200-1219.
45 DEISSLER H L, LANG G E. The protein kinase C inhibitor: ruboxistaurin[J]. Dev Ophthalmol, 2016, 55: 295-301.
46 LAM C, LOW J Y, TRAN P T, et al. The hexosamine biosynthetic pathway and cancer: current knowledge and future therapeutic strategies[J]. Cancer Lett, 2021, 503: 11-18.
47 SEMBA R D, HUANG H, LUTTY G A, et al. The role of O-GlcNAc signaling in the pathogenesis of diabetic retinopathy[J]. Proteomics Clin Appl, 2014, 8(3/4): 218-231.
48 VAIDYANATHAN K, WELLS L. Multiple tissue-specific roles for the O-GlcNAc post-translational modification in the induction of and complications arising from type Ⅱ diabetes[J]. J Biol Chem, 2014, 289(50): 34466-34471.
49 GUREL Z, SHEIBANI N. O-Linked β-N-acetylglucosamine (O- GlcNAc) modification: a new pathway to decode pathogenesis of diabetic retinopathy[J]. Clin Sci, 2018, 132(2): 185-198.
50 WANG Y X, ESHWARAN R, BECK S C, et al. Contribution of the hexosamine biosynthetic pathway in the hyperglycemia-dependent and -independent breakdown of the retinal neurovascular unit[J]. Mol Metab, 2023, 73: 101736.
51 DIERSCHKE S K, TORO A L, BARBER A J, et al. Angiotensin-(1?7) attenuates protein O-GlcNAcylation in the retina by EPAC/Rap1-dependent inhibition of O-GlcNAc transferase[J]. Invest Ophthalmol Vis Sci, 2020, 61(2): 24.
52 PETERSON S B, HART G W. New insights: a role for O-GlcNAcylation in diabetic complications[J]. Crit Rev Biochem Mol Biol, 2016, 51(3): 150-161.
53 SILVA K C, ROSALES M A, HAMASSAKI D E, et al. Green tea is neuroprotective in diabetic retinopathy[J]. Invest Ophthalmol Vis Sci, 2013, 54(2): 1325-1336.
54 ABU-AMERO K K, KONDKAR A A, CHALAM K V. Resveratrol and ophthalmic diseases[J]. Nutrients, 2016, 8(4): 200.
55 CHEN Y H, MENG J, LI H, et al. Resveratrol exhibits an effect on attenuating retina inflammatory condition and damage of diabetic retinopathy via PON1[J]. Exp Eye Res, 2019, 181: 356-366.
56 LANDON R, GUEGUEN V, PETITE H, et al. Impact of astaxanthin on diabetes pathogenesis and chronic complications[J]. Mar Drugs, 2020, 18(7): 357.
57 GELFMAN C M, GRISHANIN R, BENDER K O, et al. Comprehensive preclinical assessment of ADVM-022, an intravitreal anti-VEGF gene therapy for the treatment of neovascular AMD and diabetic macular edema[J]. J Ocul Pharmacol Ther, 2021, 37(3): 181-190.
Options
Outlines

/

〈 〉